Results 181 to 190 of about 108,257 (197)

Primary hypertrophic osteoarthropathy with myelofibrosis

Rheumatology International, 2007
Primary hypertrophic osteoarthropathy or pachydermoperiostosis is a rare congenital disease characterized by clubbing of the fingers, periostitis of the distal long bones, and hypertrophic skin changes (pachydermia) including thick folds in the skin of the face, forehead, scalp and extremities, and also joint pain.
Najmeh Nohesara, Azita Azarian, Massoud Saghafi   +2 more
openaire   +3 more sources

Renal complications of primary myelofibrosis

Leukemia & Lymphoma, 2018
Primary myelofibrosis (PMF) is a disease of the elderly, with a median age at diagnosis of 71 years.
Amanda Tchakarov, Umut Selamet, Maen Abdelrahim, Srdan Verstovsek, William F Glass, Paolo Strati, Ala Abudayyeh, Biruh Workeneh   +7 more
openaire   +3 more sources

OCULAR MANIFESTATIONS OF PRIMARY MYELOFIBROSIS

RETINAL Cases & Brief Reports, 2016
Purpose: To report ocular manifestations of idiopathic primary myelofibrosis in a patient with relapsed primary myelofibrosis. Methods: Observational case report. Results: A 57-year-old African American male with history of primary ...
Siva S R Iyer, Jordan M. Burnham, Albert L. Lin, Victor Pang, Omolola Idowu   +4 more
openaire   +3 more sources

Primary Myelofibrosis In Children

Blood, 2010
Abstract Abstract 3079 Primary myelofibrosis is a chronic myeloproliferative disorder characterized by cytopenias, leukoerythroblastosis, extramedullary hematopoiesis, hepatosplenomegaly and bone marrow fibrosis. It is a serious medical condition in adults, often requiring major interventions such as hematopoietic stem ...
Dolores Lopez-Terrada, Melissa R. DeLario, C. Renee Webb, Ramona Ataya, Andrea M. Sheehan, Carlos Vega, Alison A. Bertuch, Lakshmi Venkateswaran   +7 more
openaire   +2 more sources

An unusual presentation of primary myelofibrosis

Indian Journal of Tuberculosis, 2018
Extramedullary hematopoisis (EMH) normally occurs in fetal life, but it is pathological in later life and most of the time because of underlying marrow diseases. Sometimes EMH tissue can present with large masses which can cause compressive and constitutional symptoms. They can be wrongly diagnosed as malignancy and pulmonary tuberculosis. Here in this
Prateek Tiwari, Kanchan Muhrerkar, Vandana Mahajan   +2 more
openaire   +2 more sources

Ruxolitinib for the treatment of primary myelofibrosis

American Journal of Health-System Pharmacy, 2014
The pharmacology, pharmacokinetics, pharmacogenomics, clinical efficacy, and safety profile of ruxolitinib for the treatment of primary myelofibrosis are reviewed.Ruxolitinib, an oral tyrosine kinase inhibitor that targets the Janus-associated kinases (JAKs) 1 and 2, has been recently approved for the treatment of patients with intermediate- or high ...
openaire   +3 more sources

Primary myelofibrosis

2010
Myelofibrosis is a reactive process common to many malignant and benign disorders. Primary myelofibrosis is a chronic myeloproliferative disorder of unknown aetiology that involves a multipotent haemopoietic progenitor cell and results in abnormalities in red cell, white cell, and platelet production in association with marrow fibrosis and ...
openaire   +1 more source

Cytogenetic and molecular studies in primary myelofibrosis

Cancer Genetics and Cytogenetics, 1989
Cytogenetic and molecular data of three patients affected by primary myelofibrosis with myeloid metaplasia (PMMM) evolving to blastic crisis are reported. The cytogenetic findings were uncommon. The first patient (female) showed an idic(X)(q13) as the sole alteration in chronic phase, with an additional r(7) in 67% of the cells of the blast crisis; the
Emilia G., Temperani P., Ferrari S., Zucchini P., Tagliafico E., Selleri L., Torelli G., Artusi T., Torelli U.   +8 more
openaire   +4 more sources

Current and Emerging Therapies in Primary Myelofibrosis

Cardiovascular & Hematological Disorders-Drug Targets, 2012
Primary myelofibrosis is a clonal hematopoietic disorder characterized by ineffective hematopoiesis and progressive bone marrow fibrosis. Patients with high risk myelofibrosis as determined by their advanced age, degree of anemia, leukocytosis, constitutional symptoms and high percentage of circulating blasts have a very short median survival of 2 ...
Murali Janakiram, Radha Raghupathy, Sabarish Ayyappan   +2 more
openaire   +3 more sources

Thalidomide and lenalidomide in primary myelofibrosis.

The Netherlands journal of medicine, 2010
Primary myelofibrosis is a clonal haematopoietic stem cell disease, characterised by marrow stromal fibrosis, extramedullary haematopoiesis, splenomegaly, hepatomegaly and progressive cytopenia. Therapeutic options once cytopenia has developed are limited to supportive care, such as erythrocyte transfusions and growth factors.
Holle, N., Witte, T.J.M. de, Mandigers, C.M.P.W., Schaap, N.P.M., Raymakers, R.A.P.   +4 more
openaire   +2 more sources